Can Facet Arthroplasty Outperform TLIF for Spondy?

Key Takeaways

• TOPS achieved 85% composite clinical success vs 64% for TLIF.
• ODI improvement ≥15 points in 93% TOPS, 81% TLIF.
• Segmental motion maintained at 24 months with TOPS (≈3.86°).
• Reoperation rate lower for TOPS (5.9%) vs TLIF (8.8%).
• Study limited to 24‑month follow‑up and single‑level L4‑5 cases.

Pulse Analysis

The lumbar spine market has long been dominated by fusion technologies, especially TLIF, which address instability by eliminating motion at the affected segment. While fusion reliably reduces pain, it also creates a biomechanical cascade that can accelerate adjacent‑segment disease, a costly complication for both patients and insurers. Recent advances in posterior facet arthroplasty aim to preserve natural kinematics, positioning devices like TOPS as a disruptive alternative that aligns with the broader shift toward motion‑preserving orthopedics and minimally invasive solutions.

In the FDA‑mandated IDE trial, TOPS not only met rigorous safety benchmarks but also outperformed TLIF on a composite clinical success metric that includes reoperation avoidance, device integrity, and a ≥15‑point ODI gain. Maintaining an average flexion‑extension range of about 3.86 degrees after two years demonstrates true kinetic preservation, a claim often relegated to theoretical models. Moreover, the lower reoperation rate and comparable intra‑operative blood loss suggest that the learning curve and peri‑operative burden may be manageable for spine surgeons already comfortable with posterior approaches.

For healthcare systems, the adoption of facet arthroplasty could translate into downstream cost savings if long‑term data confirm reduced adjacent‑segment degeneration and fewer revision surgeries. Payers may view the higher upfront device cost as justified by improved functional outcomes and potential longevity. However, broader uptake will depend on extended follow‑up, reimbursement pathways, and surgeon education. As evidence accumulates, motion‑preserving technologies like TOPS are poised to reshape treatment algorithms for degenerative spondylolisthesis, offering a nuanced alternative to the one‑size‑fits‑all fusion paradigm.